Bilateral Inferior Petrosal Sinus Sampling in Corticotropin-Dependent Cushing’s Syndrome: A Single Center Experience from Western India

Naincy Purwar, Anshul Kumar, Balram Sharma, Himanshu Sharma, Sanjay Saran, Umesh Garg, Rahul Sahlot, Sandeep K. Mathur
Department of Endocrinology, S.M.S. Medical College and Hospital, Jaipur, Rajasthan, India

Abstract

Objective: Efficacy of bilateral inferior petrosal sinus sampling (BIPSS) in corticotropin-dependent Cushing’s syndrome (CS) for localization and lateralization of excess adrenocorticotropic hormone (ACTH) source, as compared to high-dose dexamethasone suppression test (HDDST) and magnetic resonance imaging (MRI) pituitary, respectively. Methodology: Thirteen patients with clinically and biochemically confirmed CS underwent HDDST, MRI pituitary, and BIPSS by an experienced team of intervention neurologist, neurosurgeon, and endocrinologist using percutaneous femoral vein approach. Results: Of 13 patients (11 adults and two children) who underwent BIPSS, raised central to peripheral ACTH ratio was achieved in 12 cases, remaining one case being ectopic ACTH secretion (EAS). However, inter IPS gradient >1.4 was achieved in 11 (91.6%) of 12 Cushing’s disease (CD) cases before vasopressin stimulation; and in 9 (75%) of 12 CD cases after vasopressin stimulation (P-value 0.583). HDDST suppression of more than 50% was present in only ten cases with CD, falsely negating CD in two cases (16.6%), sensitivity 83.3% and specificity 100%. MRI sella demonstrated pituitary microadenoma in 12 cases and macroadenoma in one case. Lateralization by BIPSS and MRI was concordant in 7 (58.3%) out of 12 cases with CD, with rate of remission after transsphenoidal surgery being higher in patients with concordant lateralization by BIPSS and MRI. Conclusions: BIPSS is an important investigation to distinguish CD and EAS. BIPSS was superior to HDDST for confirming the source of excess ACTH. Our findings favor the use of BIPSS for localization and pituitary MRI for lateralization of microadenoma.

Keywords: BIPSS-Bilateral inferior petrosal sinus sampling, CD-Cushing’s disease, EAS-ectopic ACTH secretion, ectopic ACTH syndrome, HDDST-high-dose dexamethasone suppression test, IPS-Inferior petrosal sinus, LDDST-low-dose dexamethasone suppression test

INTRODUCTION

Endogenous Cushing’s syndrome (CS) results from the overproduction of cortisol, either due to corticotropin-dependent or corticotropin-independent cause, with a prevalence of 2–3 cases/million/year. Ectopic adrenocorticotropic hormone (ACTH)-secreting tumor may remain occult for a long time, making an accurate diagnosis of corticotropin-dependent CS a challenging issue.

Dynamic gadolinium-enhanced magnetic resonance imaging (MRI) represents the foremost accurate imaging modality for pituitary adenomas. However, MRI has limited power in identifying subcentimeter ACTH-secreting microadenomas because it also identifies 10%–20% of nonfunctioning pituitary incidentalomas. Although the presence of a macroadenoma (>10 mm) is very implicative of pituitary disease, this is not true for small lesions which may also be nonsecretory incidentalomas. Hence, MRI cannot be completely relied upon to differentiate between Cushing’s disease (CD) and ectopic ACTH secretion (EAS). The diagnostic accuracy of the stimulatory and inhibitory...
biochemical hormone tests as described in literature has been 65%–100% sensitivity and 60%–100% specificity for the high-dose dexamethasone suppression test (HDDST) and 70%–93% sensitivity and 95%–100% specificity for the Corticotropin-releasing hormone (CRH) test.\textsuperscript{[5]}

The Consensus Statement on Diagnosis and Complications of CS suggests 6 mm cut off for a pituitary lesion detected by MRI to be considered corticotroph adenoma, and proceeded directly for surgery without IPSS. However, this data was mainly based on the size of pituitary lesions in healthy controls.\textsuperscript{[4]} Ten percent of the general population harbors incidental pituitary tumors\textsuperscript{[5,6]} and pituitary incidentalomas as large as 14 mm have also been seen in patients with EAS.\textsuperscript{[7,8]} The suggested 6 mm cut off provides specificity only up to 96% for accurately diagnosing CD.\textsuperscript{[9]} Hence, bilateral inferior petrosal sinus sampling (BIPSS) is taken into account to substantiate the source of ACTH as pituitary or ectopic, with high sensitivity and specificity. CRH stimulation during BIPSS has been well documented in literature for maximizing the sensitivity of BIPSS.\textsuperscript{[10]} However, due to the poor availability of CRH in our country, desmopressin and vasopressin have also been used as corticotroph stimulant during BIPSS with similar sensitivity.\textsuperscript{[10]} Vasopressin acts on V3 (arginine vasopressin receptor 1B) receptors present on corticotroph cells in the anterior pituitary and has been shown to have ACTH secretagogue effect.\textsuperscript{[10]}

In this study, we have summarized our experience of BIPSS in 13 patients with corticotropin-dependent CS and compared HDDST with BIPSS for localization of the source of excess corticotropin. We also assessed the accuracy of MRI pituitary and BIPSS in lateralizing pituitary adenoma with respect to treatment outcomes.

**Methodology**

**Subjects**

Patients admitted in the indoor facility of our department with corticotropin-dependent CS, established from clinical history and examination, basal 8 am and 11 pm serum cortisol, overnight dexamethasone suppression test (ONDST), low and high dose dexamethasone suppression test (LDDST and HDDST, respectively), and ACTH levels were recruited. After biochemical confirmation, patients underwent BIPSS after an interval of approximately 7 days.

**BIPSS procedure and interpretation**

The BIPSS procedure was performed by the same experienced team of intervention neurologist, neurosurgeon and endocrinologist. Bilateral femoral veins were accessed and catheters were maneuvered into inferior petrosal sinuses under radiological guidance. Blood was simultaneously withdrawn from both petrosal catheters and from ipsilateral peripheral veins at different time points for ACTH measurement and collected in cold test tubes. Basal samples were taken 5 min and 1 min before vasopressin stimulation; then, vasopressin (one unit diluted in 10 mL saline) was injected into a peripheral vein and repeated samples were taken after 5 min and 10 min.\textsuperscript{[10]} Blood samples were instantly cold transported to the laboratory for ACTH assay (using Immulite 1000 Chemiluminescence immunoassay). Central to peripheral ACTH ratio was calculated for right and left side. For the diagnosis of Cushing’s disease (CD), basal central to peripheral ACTH ratio was $\geq$2 and/or post-vasopressin stimulation ratio $\geq$3 was endorsed. For lateralization to a given side, a ratio of $\geq$1.4 was used. In case, these ratios were not met, the diagnosis of ectopic CS was considered.

**Treatment and outcome**

All the patients diagnosed as CD underwent transsphenoidal surgery (TSS) as per lateralization by MRI of sella. BIPSS may not reliably identify the tumor site based on side-to-side gradient of 1.4,\textsuperscript{[11-13]} and hemi-hypophysectomy based on IPSS lateralization cured only 50% of patients in one study, an outcome no better than chance.\textsuperscript{[14]} Suspected tumor tissue and pituitary tissue adjacent to the tumor was resected and pathologically examined. Therapeutic outcome was categorized as “remission” if the serum cortisol level was below 5 µg/dL measured within the first 2 weeks after TSS, and residual if not meeting the said criterion.\textsuperscript{[15-17]}

**Results**

**Baseline characteristics**

Data was collected for 13 patients who underwent BIPSS from March 2018 to March 2020. No severe adverse effects occurred in any of the patients during or after the procedure. Among the 13 patients (eleven adults and two children), 12 were female and one child was the only male patient. Mean age of study population was $31.2 \pm 11.6$ years and median duration of disease was 2.6 years. The average 8:00 am and 11 pm cortisol level was $34.63 \pm 15.76$ µg/dL and $24.40 \pm 16.68$ µg/dL, respectively. Morning fasting ACTH level ($141.20 \pm 135$ pg/mL) was elevated in all patients suggestive of ACTH-dependent CS. All but three cases had more than 50% drop in cortisol levels with HDDST. MRI sella demonstrated pituitary microadenoma in 12 cases and macroadenoma in one case. Based on abnormal clinical and chest X-ray findings, contrast-enhanced CT chest was done for two cases (case five and seven in Table 1) that demonstrated a space-occupying lesion in right lung in both the cases. Also, one case (case no 8 in Table 1) had a CT abdomen done before presenting to us. It showed an adrenal stalk lesion, which was, however, not supported by our biochemical findings. Detailed clinical characteristics and Cortisol suppression tests are listed in supplementary Tables 2 and 3 respectively.

**Results of BIPSS before and after vasopressin stimulation**

Inferior petrosal sinuses could be successfully catheterized in all our patients. Based on ACTH values, 12 patients were diagnosed as CD and one patient (case five in Table 1) as EAS although MRI sella showed 1 × 1 mm microadenoma in this case also. Raised central/peripheral ACTH ratio was achieved in all twelve CD cases, both before and after vasopressin stimulation. Inter IPS gradient $>1.4$ was achieved in 11 (91.6%)
of 12 CD cases (excluding one case of EAS) before vasopressin stimulation; and in nine (75%) of 12 CD cases after vasopressin stimulation (P-value 0.583). Detailed results are available in supplementary Tables 4 and 5.

**Sensitivity and specificity of HDDST versus BIPSS for localization of CD**

HDDST has previously been the mainstay of biochemical differential diagnosis between the pituitary and ectopic ACTH-dependent syndrome. In our series, HDDST suppression >50% was present in only 10 out of these 12 cases, falsely negating CD in two cases (16.7%). The sensitivity and specificity of HDDST turned out to be 83.3% and 100%, respectively. However, BIPSS could correctly diagnose CD in all 12 cases and was found to be superior to HDDST for differentiating CD and EAS.

**Adenoma lateralization and treatment outcomes**

In our cohort, MRI sella revealed a pituitary microadenoma in twelve cases, including one case (case five) with EAS and pituitary macroadenoma in one case (case twelve in Table 1). Lateralization by BIPSS and MRI was concordant in seven (58.3%) out of 12 cases with CD. Out of the total 13 patients who underwent BIPSS, two patients (case 5 with EAS and case 10 with CD in Table 1) expired before definitive surgery owing to acute cardiovascular complications. Of the remaining 11 CD patients, two (case 12 and 13 in Table 1) denied surgery and were started on medical management with oral ketoconazole. Nine patients underwent TSS based on MRI localization and were postoperatively confirmed with biopsy of excised tissue. Five of these are in remission while four patients have residual disease. It was observed that 4 out of 5 (80%) patients in remission had concordant lateralization results on MRI sella and BIPSS for corticotroph adenoma, while 50% cases with residual disease had discordant lateralization on IPSS and MRI sella (P-value 0.812). Case three and case four were pediatric cases and underwent TSS followed by hypocortisolism and hypopituitarism. Both the children are in remission and under regular follow-up.

Refer to Table 1 for the results of HDDST, lateralization on BIPSS and MRI, and treatment outcome of study cohort.

### Discussion

CS is easily diagnosed clinically owing to its characteristic features. However, anatomical localization of the source of excess ACTH is challenging. Definite treatment of CS is surgical removal of ACTH-secreting lesion, a prerequisite for which is distinct localization of ACTH-secreting source. Pituitary MRI localizes microadenoma in only 50%–60% of the cases attributable to the small size of corticotroph adenoma which can lead to falsely negative diagnosis. [6,18]

HDDST >50% suppression has long been used as a criterion to distinguish EAS with CD and holds substantial importance in the management of patients with ACTH-dependent CS when facilities for BIPSS are not readily available. It could correctly predict pituitary adenoma in 10 out of 12 cases with CD in our series, with a false-negative result in two (16.6%) cases. HDDST had a sensitivity of 83.3% and specificity of 100% as compared to BIPSS which was 100% sensitive and specific for
distinguishing CD and EAS in our cohort. As evident in literature also, BIPSS is superior to HDDST for confirming CD and should be preferred at centers where the facility and technical expertise is available. Though we did not encounter any procedure-related complication in our cohort, transient nausea, vomiting, ear discomfort, and

| Table 3: Cortisol suppression tests and pituitary imaging |
|----------------|---------|----------------|----------------|----------------|----------------|----------------|
| Case No. | 8:00 am Cortisol (µg/dL) | 11:00 pm cortisol (µg/dL) | ONDST (µg/dL) | LDDST (µg/dL) | HDDST (µg/dL) | ACTH (pg/mL) |
|----------|----------------|----------------|-------------|-------------|-------------|-------------|
| 1. | 33.5 | 31.07 | 21.09 | 23.09 | 2.95 | 156 |
| 2. | 26.6 | 21.80 | 20.06 | 16.91 | 13.7 | 53.1 |
| 3. | 37.08 | 18.69 | 25.78 | 29.32 | 9.88 | 109 |
| 4. | 46.31 | 22.10 | 9.25 | 11.96 | 14.63 | 79.6 |
| 5. | >75 | >75 | >75 | >75 | 61.26 | 470 |
| 6. | 16.7 | 15.32 | 12.29 | 5.40 | 1.29 | 102 |
| 7. | 35.4 | 8.90 | 3.56 | 17.10 | 7.6 | 69.7 |
| 8. | 20.8 | 16.11 | 5.36 | 7.45 | 5.01 | 32.4 |
| 9. | 35.1 | 24.14 | 12.50 | 10.30 | 14.91 | 406 |
| 10. | 31.14 | 27.1 | 29.9 | 20.84 | 26.01 | 97.9 |
| 11. | 29.85 | 16.24 | 8.82 | 13.54 | 10.58 | 99 |
| 12. | 14.42 | 10.53 | 4.86 | 3.63 | 4.5 | 65.3 |
| 13. | 48.25 | 30.28 | 41.94 | 18.46 | 8.35 | 95.9 |

| Case No. | MRI Sella |
|----------|-----------|
| 1. | 4 × 5 mm left microadenoma |
| 2. | 4 × 3 mm right microadenoma |
| 3. | 5 × 3 mm left microadenoma |
| 4. | 5.8 × 4 mm right microadenoma |
| 5. | 5 × 3 mm right microadenoma |
| 6. | 6 × 6 mm microadenoma |
| 7. | 9 × 8 mm left microadenoma |
| 8. | 6 × 9 × 7 mm central and left microadenoma |
| 9. | 3 × 6 × 2 mm left microadenoma |
| 10. | 6 × 6 mm microadenoma |
| 11. | 3 × 2.8 mm microadenoma |
| 12. | 28 × 21 × 14 mm macroadenoma |
| 13. | 6.1 × 6 mm microadenoma |

| Table 4: Adrenocorticotropic hormone values of basal and post vasopressin stimulation from both petrosal sinuses and femoral veins |
|----------------|---------|---------|---------|---------|---------|---------|
| Case No. | −05 min | −01 min | +05 min | +10 min |
|----------|---------|---------|---------|---------|
| Right | Left | Right | Left | Right | Left | Right | Left |
| 1. | 4.35 | 11 | 1.89 | 11.25 | 1.69 | >14.5 | 1.5 | >12.65 |
| 2. | 1.94 | 22.6 | 9.63 | 22.9 | >31.25 | 30.52 | 2.9 | 1.31 |
| 3. | 3.99 | 0.39 | 4.13 | 0.35 | 3.81 | 0.60 | 6.8 | 1.54 |
| 4. | 9.9 | 1.3 | 4.47 | 4.07 | 3.0 | 1.16 | 1.03 | 0.94 |
| 5. | 1.35 | 1.34 | 1.06 | 1.06 | 1.024 | 1.01 | 1.03 | 0.94 |
| 6. | 1.92 | 1.75 | 1.82 | 2.11 | 19.11 | 11.19 | 3.14 | 3.5 |
| 7. | 9.61 | 4.8 | 8.4 | 7.4 | 7.96 | 7.96 | 1.5 | 6.9 |
| 8. | 2.10 | 1.47 | 1.97 | 1.94 | 15.2 | 10.5 | 7.8 | 6.6 |
| 9. | 16.8 | 27.1 | 20.2 | 25.4 | 11.1 | 15.3 | 3.6 | 10.4 |
| 10. | 5.07 | 9.33 | 4.3 | 3.55 | 5.14 | 5.41 | 4.32 | 4.6 |
| 11. | 8.78 | 0.49 | 12.81 | 1.3 | 9.06 | 1.99 | 19.98 | 1.25 |
| 12. | 3.67 | 3.38 | 3.76 | 2.47 | 3.35 | 2.48 | 3.14 | 2.10 |
| 13. | 3.60 | 0.27 | 7.39 | 1.31 | 11.46 | 4.42 | 6.86 | 2.19 |

| Case No. | Inter IPS gradient |
|----------|------------------|
| −05 min | −01 min | +05 min | +10 min |
| 1. | 5.1 | >8.56 | >8.44 |
| 2. | 2.38 | 0.97 | 1.01 |
| 3. | 11.83 | 6.26 | 2.21 |
| 4. | 1.12 | 2.5 | 4.4 |
| 5. | 0.99 | 1.01 | 1.09 |
| 6. | 1.16 | 1 | 1.11 |
| 7. | 1.14 | 1 | 4.5 |
| 8. | 1.01 | 1.43 | 1.17 |
| 9. | 1.25 | 1.37 | 2.82 |
| 10. | 1.22 | 1.05 | 1.06 |
| 11. | 9.68 | 4.5 | 6.78 |
| 12. | 1.51 | 1.35 | 1.49 |
| 13. | 5.6 | 2.59 | 3.125 |
In our cohort, vasopressin stimulation (1 unit in 10 mL saline) during BIPSS did not provide any added benefit in localization or lateralization of corticotroph adenoma. BIPSS was found to be superior to HDDST for localization and confirmation of CD with sensitivity of 100% as compared to HDDST with sensitivity of only 83.3%. MRI is more accurate for lateralization of corticotroph adenoma and forms basis for surgery. Favorable treatment outcomes and remission rate after TSS are higher in patients with concordant lateralization of pituitary adenoma by BIPSS and MRI. Hence, BIPSS may be recommended in all patients with ACTH-dependent CS, provided our findings are validated in larger cohorts as our sample size was small with only thirteen cases.

**Conclusions**

With the ability to confirm the central secretion of ACTH, BIPSS is an important investigation to distinguish CD and EAS. In our cohort, vasopressin stimulation (1 unit in 10 mL saline) during BIPSS did not provide any added benefit in localization or lateralization of corticotroph adenoma. BIPSS was found to be superior to HDDST for localization and confirmation of CD with sensitivity of 100% as compared to HDDST with sensitivity of only 83.3%. MRI is more accurate for lateralization of corticotroph adenoma and forms basis for surgery. Favorable treatment outcomes and remission rate after TSS are higher in patients with concordant lateralization of pituitary adenoma by BIPSS and MRI. Hence, BIPSS may be recommended in all patients with ACTH-dependent CS, provided our findings are validated in larger cohorts as our sample size was small with only thirteen cases.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Lila AR, Sarathi V, Jagtap VS, Bandgar T, Menon P, Shah NS. Cushing’s syndrome: Stepwise approach to diagnosis. Indian J Endocrinol Metab 2011;15 Suppl 4(Suppl 4):S317-21.
2. Buurman H, Saeuer W. Subclinical adenomas in postmortem pituitaries: Classification and correlations to clinical data. Eur J Endocrinol

---

Table 5: Highest central to peripheral adrenocorticotropic hormone ratio and interpetrosal adrenocorticotropic hormone gradient

| Highest central/peripheral ACTH ratio (basal) | Highest central/peripheral ACTH ratio (poststimulation) | Highest inter IPS ratio (basal) | Highest inter IPS ratio (poststimulation) | Diagnosis* | Lateralization |
|---------------------------------------------|--------------------------------------------------------|---------------------------------|----------------------------------------|------------|--------------|
| 11                                          | >14.5                                                  | 5.1                             | >8.56                                  | CD         | Left         |
| 22.92                                       | 31.25                                                  | 11.6                            | 1.01                                   | CD         | Left         |
| 4.13                                        | 3.81                                                   | 11.83                           | 6.26                                   | CD         | Right        |
| 9.9                                         | 6.8                                                    | 8.8                             | 4.4                                    | CD         | Right        |
| 1.35                                        | 1.03                                                   | 1.16                            | 1.11                                   | EAS        | None         |
| 2.11                                        | 3.5                                                    | 1.16                            | 1.11                                   | CD         | Left         |
| 9.61                                        | 7.96                                                   | 1.97                            | 4.5                                    | CD         | Left         |
| 2.10                                        | 15.2                                                   | 1.42                            | 1.43                                   | CD         | Right        |
| 27.1                                        | 15.3                                                   | 1.60                            | 2.82                                   | CD         | Left         |
| 9.33                                        | 5.41                                                   | 1.84                            | 1.06                                   | CD         | Left         |
| 12.81                                       | 19.98                                                  | 17.83                           | 6.78                                   | CD         | Right        |
| 3.76                                        | 3.35                                                   | 1.51                            | 1.49                                   | CD         | Right        |
| 7.39                                        | 11.46                                                  | 12.9                            | 3.125                                  | CD         | Right        |

*CD-Cushing’s disease; EAS- Ectopic ACTH secretion.
3. Mehta GU, Montgomery BK, Raghavan P, Sharma S, Nieman LK, Patronas N, et al. Different imaging characteristics of concurrent pituitary adenomas in a patient with Cushing’s disease. J Clin Neurosci 2015;22:891-4.

4. Pecori FG, Cavallo LM, Tortora F, Pivonello R, Colao A, Cappabianca P, et al. The role of inferior petrosal sinus sampling in ACTH-dependent Cushing’s syndrome: Review and joint opinion statement by members of the Italian society for endocrinology, Italian society for neurosurgery, and Italian society for neuroradiology. Neurolour Focus 2015;38:E5.

5. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, et al. Diagnosis and complications of Cushing’s syndrome: A consensus statement. J Clin Endocrinol Metab 2003;88:5593-5602.

6. Hall WA, Luciano MG, Doppman JL, Patronas NJ, Oldfield EH. Pituitary magnetic resonance imaging in normal human volunteers: Occult adenomas in the general population. Ann Intern Med 1994;120:817-20.

7. Chong BW, Kucharczyk W, Singer W, George S. Pituitary gland MR: A comparative study of healthy volunteers and patients with microadenomas. AJNR Am J Neuroradiol 1994;15:675-9.

8. Yogi-Moreen D, Habra MA, Faiman C, Bena J, Hatipoglu B, Kennedy L, et al. Pituitary MRI findings in patients with pituitary and ectopic ACTH-dependent Cushing syndrome: Does a 6-mm pituitary tumor size cut-off value exclude ectopic ACTH syndrome? Endoer Pract 2015;21:1098-103.

9. Ilias I, Torpy DJ, Pacak K, Mullen N, Wesley RA, Nieman LK. Cushing’s syndrome due to ectopic corticotropin secretion: Twenty years’ experience at the National institutes of health. J Clin Endocrinol Metab 2005;90:4955-62.

10. Kotwal N, Kumar Y, Upreti V, Singh A, Garg MK. Bilateral inferior petrosal sinus sampling using vasopressin. Indian J Endocrinol Metab 2016;20:399-403.

11. Nieman KL, Biller BMK, Finding JW, Murad MH, Price JN, Savage Mo, et al. Treatment of Cushing’s syndrome: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2013;98:2285-31.

12. Wind JJ, Lonser RR, Nieman LK, DeVroom HL, Chang R, Oldfield EH. The lateralization accuracy of inferior petrosal sinus sampling in 501 patients with Cushing’s disease. J Clin Endocrinol Metab 2013;98:2285-93.

13. Storr HL, Alexandraki KI, Martin L, Isidori AM, Kaltsas GA, Monson JP, et al. Comparisons in the epidemiology, diagnostic features and cure rate by transsphenoidal surgery between pediatric and adult-onset Cushing’s disease. Eur J Endocrinol 2011;164:667-74.

14. Liu C, Lo JC, Dowd CF, Wilson CB, Kunwar S, Aron DC, et al. Cavernous and inferior petrosal sinus sampling in the evaluation of ACTH-dependent Cushing’s syndrome. Clin Endocrinol (Oxf) 2004;61:478-86.

15. Swearingen B, Katznelson L, Miller K, Grinspoon S, Waltman A, Dorer DJ, et al. Diagnostic errors after inferior petrosal sinus sampling. J Clin Endocrinol Metab 2004;89:3752-63.

16. Batista LD, Oldfield EH, Keil MF, Stratakis CA. Postoperative testing to predict recurrent curing Cushing disease in children. J Clin Endocrinol Metab 2009;94:2757-65.

17. Lindsay JR, Oldfield EH, Stratakis CA, Nieman LK. The postoperative basal cortisol and CRH tests for prediction of long-term remission from Cushing’s disease after transphenoidal surgery. J Clin Endocrinol Metab. 2011;96:2057-64.

18. Kaskarelis IS, Tsatalou EG, Benakis SV, Malagari K, Komninos I, Vassiliadi D, et al. Bilateral inferior petrosal sinuses sampling in the routine investigation of Cushing’s syndrome: A comparison with MRI. AJR Am J Roentgenol 2006;187:562-70.

19. Calao A, Pivonello R, Giraldi FP, Cavagnini F, Lombardi G, Study Group of the Italian Endocrinology Society on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. Inferior petrosal sinus sampling in the differential diagnosis of Cushing’s syndrome: Results of an Italian multicenter study. Eur J Endocrinol 2001;144:499-507.

20. Carmody D, Hannon MJ, Thompson C. Vasopressin, diabetes insipidus and the syndrome of inappropriate ADH secretion. In: Jameson JL, DeGroot LJ, editors. Endocrinology Adult and Pediatrics. 6th ed. Philadelphia: Elsevier Saunders; 2010. p. 386-99.

21. Tsagarakis S, Vassiliadi D, Kaskarelis IS, Komninos J, Souvatzoglou E, Thalassinos N. The application of the combined corticotropin-releasing hormone plus desmopressin stimulation during petrosal sinus sampling is both sensitive and specific in differentiating patients with Cushing’s disease from patients with the occult ectopic adrenocorticotropic syndrome. J Clin Endocrinol Metab 2007;92:2080-6.

22. Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing’s states. Endocr Rev 1998;19:647-72.

23. Javorsky BR, Findling JW. Inferior petrosal sampling for the differential diagnosis of ACTH-dependent Cushing’s syndrome. In: Bronstein MD, ed. Cushing’s Syndrome: Pathophysiology, Diagnosis and Treatment. 1st ed. New York: Humana Press, 2010. p. 105.

24. Lefournier V, Martinie M, Vasdev A, Bessou P, Passagia JG, Moleur FL, et al. Accuracy of bilateral inferior petrosal or cavernous sinuses sampling in predicting the lateralization of Cushing’s disease pituitary microadenoma: Influence of catheter position and anatomy of venous drainage. J Clin Endocrinol Metab 2003;88:196-203.

25. Deipolyi A, Bailin A, Hirsch JA, Walker TG, Oklu R. Bilateral inferior petrosal sinus sampling: Experience in 327 patients. J Neurointervent Surg 2017;9:196-9.

26. Chen S, Chen K, Lu L, Zhang X, Tong A, Pan H, et al. The role of inferior petrosal sinus sampling in ACTH-dependent Cushing’s syndrome. Clin Endocrinol (Oxf) 2020;93:582-91.